25 July 2018 - - San Diego-based biopharmaceutical company has closed a USD 230m series B preferred stock financing led by Hillhouse Capital, the company said.
New investors participating in this financing include among others, a wholly-owned subsidiary of the Abu Dhabi Investment Authority, Invus, The Baupost Group and Polaris Partners.
Gossamer Bio's existing investors, ARCH Venture Partners and Omega Funds, also meaningfully participated.
Proceeds from this financing will be used to continue the rapid growth of the company, progress clinical trials for multiple early and late-stage drug candidates, and to secure additional business development opportunities.
Gossamer Bio is focused on discovering, developing, and commercialising immunology-based therapeutics in the autoimmune, allergy/inflammation, and immuno-oncology disease areas.